Please login to the form below

Not currently logged in
Email:
Password:

Xellia forms scientific advisory board

Will further progress on innovative anti-infectives

Xellia Pharmaceuticals, who have a focus on anti-infective treatments, has announced the formation of a new scientific advisory board.

The SAB will bring together international scientific and clinical advisors with expertise in infectious diseases, clinical microbiology, respiratory medicines and drug research and development.

Carl-Åke Carlsson, CEO of Xellia, said: “We welcome the members of the new scientific advisory board to the company.

“Their scientific and clinical insight and guidance combined with our specialist expertise will help us improve efficacy, increase safety profiles and reduce the side effects of existing molecules and develop new drugs to help tackle the global crisis of antimicrobial resistance.”

  • Dr Andreas Rummelt, a member of Xellia Board of Directors supporting R&D
  • Professor Gerhard Winter, Department of Pharmacy, Ludwig Maximilian University of Munich, Munich, Germany
  • Professor Christoph Tang, The Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
  • Dr Tania Pressler, Chief Attending Physician, Rigshospitalet, Copenhagen, Denmark
  • Professor Keith S Kaye, Division of Infectious Diseases and Department of Medicine at Wayne State University and Detroit Medical Center, Detroit, US
  • Professor Anne O'Donnell, Professor and Chief, Division of Pulmonary, Critical Care, and Sleep Medicine, Georgetown University Hospital, Washington DC, US
  • Professor Arjana Tambić Andrašević, Head of the Department of Clinical Microbiology at the University Hospital for Infectious Diseases, Zagreb, Croatia.

The board, chaired by Professor George Griffin, emeritus professor of infectious disease and medicine at St George's, University of London, added: “Xellia has attracted an impressive board of scientific and clinical advisors, which I am proud to chair.

“Antimicrobial resistance is a huge area of unmet medical need and one of the greatest threats to human health. On behalf of the board, we look forward to working with and guiding Xellia in this valuable area of development.”

18th December 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics